HCV CASCADE OF CARE OF PEOPLE ADMITTED TO DRUG TREATMENT (2015-2019) IN CATALONIA

Authors: Reyes-Urueña J1,2,3, Egea-Cortés L1,3, Muñoz R3, Majo X3, Buira E3, Forero V3, Manzanares-Laya S3, Prat A4, Umbria M4, Vela E5, Clères M5, Casabona J1,2,3,6, Colom J3.

1 Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Catalonia Public Health Agency (ASPCAT), Badalona, Spain;
2 Group 27, Biomedical Research Networking Centre in Epidemiology and Public Health (CIBERESP), Institut de Salud Carlos III, Madrid, Spain;
3 Programme for Prevention, Control and Treatment of HIV, STIs and Viral Hepatitis, ASPCAT, Barcelona, Spain;
4 Área del Medicament, Catsalut, Barcelona, Spain;
5 Sistemes d’informació Catsalut, Barcelona, Spain;
6 Dept Paediatrics, Obstetrics and Gynaecology, and Preventive Medicine, Univ Autonoma de Barcelona, Bellaterra, Spain.

Background: People who use drugs (PWUD) have high rates of hepatitis C virus (HCV) infection. This study aims to characterize the HCV cascade of care of people admitted to drug treatment in Catalonia, Spain, by main drug of consumption.

Methods: Data from PWUD admitted to the 61 drug treatment centers (01/2015–12/2019) were derived and linked from three databases: The drug information System; Catalun health surveillance system; and HCV treatment registry. Results are based on main drug of consumption. The cascade was defined in four steps: diagnosis of HCV; initiation of treatment; cure and reinfection. Predictors of HCV treatment access were identified using a multivariable regression model.

Results: 44,306 PWUD were admitted to treatment: 9.6% (4,265) for heroin, 45.8% (20,282) alcohol; 14.3% (6,323) cannabis; 21.2% (9,384) cocaine and 4.3% (1,889) tobacco. Overall, 9.7% (4,278) had a diagnosis of HCV, 46.6% (1,993) had started HCV treatment, 83% (1,053) were cured and 1% (8) were reinfelected. HCV cascade by main drug: heroin: 47% (2,004), 51.2% (1,027), 82% (410), no reinfections; alcohol: 5% (1,094), 40% (438), 316 (84%), and 1% (4); cannabis: 3% (173), 45% (78), 90% (57), no reinfections; cocaine: 5% (471), 44% (209), 82% (121), and 2% (3); and tobacco: 5% (93), 54% (50), 40 (98%), no reinfections, respectively. In multivariable analyses, human immunodeficiency virus seropositivity, imprisonment and tobacco users were independently and positively associated with HVC treatment access (P<.001), whereas being a woman was independently and negatively associated with HCV treatment access (P<.001).

Conclusion: Less than a half of those aware of their HCV infection had engaged in treatment, the lowest percentage is among alcohol abuse patients. Targeted interventions to increase access to treatment among PWUD are essential to reach the WHO target of elimination by 2030.

Disclosure of Interest Statement:
No disclosures of interest.